Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Qingdao Vland Biotech (SHSE:603739) Stock Falls 18% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. To wit, the Qingdao Vland Biotech INC. (SHSE:603739) share price managed to fall 60% over five long years. We certainly feel for shareholders who bought near the top. We also note that the stock has performed poorly over the last year, with the share price down 35%. The falls have accelerated recently, with the share price down 30% in the last three months.
一般而言,长期投资是必经之路。但在此过程中,一些股票将表现不佳。也就是说,青岛威兰生物技术有限公司(上海证券交易所代码:603739)股价在漫长的五年中成功下跌了60%。对于在接近顶部买入的股东,我们当然有同感。我们还注意到,该股去年表现不佳,股价下跌了35%。最近跌势加速,股价在过去三个月中下跌了30%。
With the stock having lost 18% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
由于该股在过去一周下跌了18%,值得一看业务表现,看看是否有任何危险信号。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
尽管一些人继续教导高效市场假说,但事实证明,市场是反应过度的动态系统,投资者并不总是理性的。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。
During the five years over which the share price declined, Qingdao Vland Biotech's earnings per share (EPS) dropped by 12% each year. Readers should note that the share price has fallen faster than the EPS, at a rate of 17% per year, over the period. This implies that the market was previously too optimistic about the stock.
在股价下跌的五年中,青岛威兰德生物科技的每股收益(EPS)每年下降12%。读者应注意,在此期间,股价的下跌速度快于每股收益,每年下降17%。这意味着市场此前对该股过于乐观。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下图中看到 EPS 随时间推移的变化(点击图表查看确切值)。
Dive deeper into Qingdao Vland Biotech's key metrics by checking this interactive graph of Qingdao Vland Biotech's earnings, revenue and cash flow.
查看这张青岛威兰德生物的收益、收入和现金流的交互式图表,深入了解青岛威兰德生物的关键指标。
A Different Perspective
不同的视角
While the broader market lost about 17% in the twelve months, Qingdao Vland Biotech shareholders did even worse, losing 34% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Qingdao Vland Biotech better, we need to consider many other factors. Take risks, for example - Qingdao Vland Biotech has 2 warning signs we think you should be aware of.
尽管整个市场在十二个月中下跌了约17%,但青岛Vland Biotech的股东表现更糟,损失了34%(甚至包括股息)。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中10%的年化亏损还要糟糕。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股以期出现转机。长期跟踪股价表现总是很有意思的。但是,要更好地了解青岛威兰德生物科技,我们需要考虑许多其他因素。例如,冒险吧——青岛威兰德生物科技有两个警告信号,我们认为你应该注意。
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。